Other

Commonwealth Scientific and Industrial Research Organisation

Ludwig Institute for Cancer Research Limited

Ym Biosciences Australia Pty Ltd.

Amrad Operations Pty Ltd

Frank Koentgen Pty Ltd.

Herbert Rudolf Treutlein

Frank Koentgen

Gabriele Maria Suess

David Mathew Tarlinton

Andrew Frederick Wilks

Christopher John Burns

Antony Wilks Burgess

Xianyong Bu

Jun Zeng

Marcel Robert Kling

Neil Moreton McKern

Thomas Peter John Garrett

Thomas Charles Elleman

Robert Nicholas Jorissen

Vidanagamage Chandana Epa

Meizhen Lou

Michelle Leanne Styles

Colin Lesley Ward

A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, Calkyl, O, S, SO, CO or CS and X, X, Xand Xare optionally substituted by 9 specific substituents or one can be nitrogen. Compositions comprising a carrier and at least one compound of formula (I) are also provided. Further provided are methods of treating tyrosine kinase-associated disease states by administering a compound of formula (I) and methods of suppressing the immune system of a subject by administering a compound of formula (I). 

Benzimidazoles as selective kinase inhibitors

The present invention relates to a method of designing compounds able to bind to a molecule of the EGF receptor family and to modulate the activity mediated by the receptor molecule based on the 3-D structure coordinates of the EGF receptor crystal of.

Method of designing agonists and antagonists to EGF receptor family

The present invention relates generally to a growth factor precursor and its use to select production of antigen specific catalytic antibodies. Such catalytic antibodies are produced following B cell activation and proliferation induced by catalytic cleavage products of a target antigen portion of the growth factor precursor of the present invention. A particularly useful form of the growth factor precursor is as a nucleic acid vaccine. The nucleic acid vaccine of the present invention preferably further comprises a molecular adjuvant. Another aspect of the present invention comprises a growth factor precursor in multimeric form. The growth factor precursor of the present invention is useful for generating catalytic antibodies for both therapeutic, diagnostic and industrial purposes.

Catalytic antibodies and a method of producing same

The present invention is directed generally to catalytic antibodies and, more particularly, to a novel method of producing same. The method of the present invention is predicated in part on the exploitation of the products of catalysis to induce B cell mitogenesis. In a preferred embodiment, a growth factor having an ability to induce B cell mitogenesis is linked to a target antigen to which catalytic antibodies are sought. B cell mitogenesis is then dependent on the catalytic cleavage of the antigen portion of the growth factor by catalytic antibodies on the surface of B cells. The method of the present invention is useful for generating catalytic antibodies for both therapeutic and diagnostic purposes.

Growing community of inventors

Moonee Ponds, Australia

Herbert Rudolf Treutlein